Key result
DNMT3A and ASXL1 CHIP mutations are linked to ~14% higher incident dementia risk.
Why the study?
Although clonal hematopoiesis of indeterminate potential (CHIP) is a recognized risk factor for cardiovascular disease and systemic inflammation, its gene-specific impact on incident dementia and its interaction with cardiovascular disease remained unclear.
Is gene-specific clonal hematopoiesis of indeterminate potential (CHIP) associated with an increased risk of incident dementia in adults without prevalent dementia, and does this association differ by cardiovascular disease status?
Cohort (n=494,866)
Yes
Is gene-specific clonal hematopoiesis of indeterminate potential (CHIP) associated with an increased risk of incident dementia in adults without prevalent dementia, and does this association differ by cardiovascular disease status?
Answers are grounded in this paper and cite their sources.
Clonal hematopoiesis of indeterminate potential (specifically DNMT3A and ASXL1 mutations) is an independent predictor of incident dementia, with the risk being most pronounced in individuals without major cardiovascular disease.
Introduction Clonal hematopoiesis of indeterminate potential (CHIP) is a recognized risk factor for cardiovascular disease and systemic inflammation. However, its gene-specific impact on dementia and interaction with cardiovascular disease remain unclear. We investigated the association between gene-specific CHIP and incident dementia, and evaluated whether these associations differ according to cardiovascular disease. Methods We analyzed 494,866 participants (mean age 56.4 years) from the UK Biobank without prevalent dementia at baseline. CHIP was defined as a variant allele frequency ≥2%, and categorized according to genes (DNMT3A, TET2, ASXL1, JAK2). The study assessed the incidence of all-cause dementia, its gene-specific associations, and differential risks according to cardiovascular disease. Results During a median follow-up of 15.7 years (IQR 14.9–16.4), DNMT3A and ASXL1 mutations were independently associated with an increased risk of incident dementia, with adjusted hazard ratios (aHR) of 1.14 (95% confidence interval [CI] 1.03–1.27) and 1.29 (95% CI 1.04–1.60), respectively. Participants without cardiovascular disease showed a significant association between CHIP and incident dementia. In subgroup analyses, significant risks were identified in those without hypertension (aHR 1.16, 95% CI 1.00–1.35), coronary artery disease (aHR 1.15, 95% CI 1.03–1.28), or atrial fibrillation (aHR 1.16, 95% CI 1.05–1.28). However, participants with cardiovascular disease showed no statistically significant association between CHIP and dementia. Conclusion Clonal hematopoiesis of indeterminate potential, particularly DNMT3A and ASXL1 mutations, is an independent predictor of incident dementia. The impact of CHIP for dementia is most pronounced in individuals without major cardiovascular disease such as hypertension, coronary artery disease, or atrial fibrillation.Table 2.IR and HR for incident dementiaFigure 2.Subgroup analysis
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) conducted a cohort in Clonal hematopoiesis of indeterminate potential (CHIP) and incident dementia (n=494,866). Gene-specific clonal hematopoiesis of indeterminate potential (CHIP: DNMT3A, TET2, ASXL1, JAK2; VAF ≥2%) vs. No CHIP was evaluated on Incidence of all-cause dementia (aHR 1.14 (DNMT3A); aHR 1.29 (ASXL1), 95% CI 1.03-1.27 (DNMT3A); 1.04-1.60 (ASXL1)). DNMT3A and ASXL1 CHIP mutations independently increased incident dementia risk, particularly in those without cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: